Global Undifferentiated Pleomorphic Sarcoma Therapeutics Market - 2022-2029

Global Undifferentiated Pleomorphic Sarcoma Therapeutics Market - 2022-2029

Market Overview

The Undifferentiated Pleomorphic Sarcoma Therapeutics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Soft tissue cancers include malignant fibrous histiocytoma, often undifferentiated pleomorphic sarcoma. It's rare cancer that frequently metastasizes to other body regions and returns after treatment. Surgery to remove the cancer cells is typically the first step in treating undifferentiated pleomorphic sarcoma. The use of medications (systemic therapies), such as chemotherapy, targeted therapy, and immunotherapy, is another possibility (most of the drugs are in clinical trials).

Market Dynamics

Increasing clinical trials for undifferentiated pleomorphic sarcoma is expected to drive market growth.

On July 21, 2020, Tracon Pharmaceuticals Inc. conducted a pivotal cohort study evaluating the use of envafolimab alone or in combination with ipilimumab for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy. The research is in Phase 2. Moreover, In a phase II trial, the National Cancer Institute (NCI) and M.D. Anderson Cancer Center examined the effects of sintilimab in treating patients with undifferentiated pleomorphic sarcoma that has metastasized to other parts of the body, spread locally to nearby tissue or lymph nodes, returned (recurrent), or cannot be surgically removed (unresectable). Sintilimab, a monoclonal antibody used in immunotherapy, may aid the body's immune system combat the disease and prevent tumor cells from proliferating and spreading. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Side effects of the drugs, lack of awareness about the disorder, limited availability of required healthcare facilities and strict government restrictions on drug approval are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The undifferentiated pleomorphic sarcoma therapeutics market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, reimbursement scenario, pricing analysis, pipeline analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has affected every aspect of cancer care. As a result, there is a delay in treatment or loss of follow-up. Studies from pandemic-affected areas show diminution in undifferentiated pleomorphic sarcoma surgeries. There was a lack of patient care in diagnostic and surgical procedures and a delay in adjuvant therapy. This adversely affects the prognosis of aggressive malignancies and has resulted in upstaging of the tumour and poor prognosis.

Moreover, research laboratories have been shut down, resulting in delays in clinical trials. In contrast, virtual multidisciplinary cancer team meeting technology discussed individual treatment plans and logistics. Patients with high-risk rapidly proliferating tumors were considered for radiotherapy, and shortening treatment duration by hypofractionation has shown promising results. They also help in better allocation of resources and shorten the treatment course. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Radiation therapy segment is expected to hold the largest market share in undifferentiated pleomorphic sarcoma therapeutics market

The radiation therapy segment is expected to dominate in 2021. The segment is benefited because, in the multimodal treatment of soft tissue sarcomas, radiotherapy (RT) is becoming more important. Intensity-modulated, image-guided, and stereotactic radiation are a few technological advancements that have greatly boosted radiotherapy's potential during the past 20 years and improved patient care. They have permitted either dose escalation (with improved efficacy) or toxicity reduction (with the consequent improved functional outcome). Moreover, healthcare providers usually recommend radiation therapy. This powerful combination allows the best chance of preventing the sarcoma from returning to the same area. For instance, external beam radiation is a type of radiation that comes from a machine that moves around you as you lie on a table. The device targets specific areas of the body with radiation. A sarcoma may be shrunk with radiation before surgery to facilitate removal. It can also be used to eliminate cancer cells following surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global undifferentiated pleomorphic sarcoma therapeutics market

In 2021, North America accounted for the highest revenue share. The rising geriatric population, increasing clinical trials, advancement in the diagnosis of sarcoma, and adoption of new imaging guidelines in the region are some factors the market is expected to boost in the forecast period. For instance, according to the Population Reference Bureau, the number of Americans 65 and older will nearly double from 52 million in 2018 to 95 million by 2060, increasing their percentage of the overall population from 16 percent to 23 percent. There is a diversity gap across generations despite the older adult population being more diverse. The racial/ethnic makeup of the population under 18 is changing more quickly than the group over 65.

Moreover, the following imaging suggestions are part of the clinical practice guidelines provided by the National Comprehensive Cancer Network (NCCN) for STS of the extremities, superficial trunk, head, and neck. All lesions with a decent cancer risk should have sufficient primary tumor imaging. Imaging examinations should include cross-sectional magnetic resonance imaging (MRI) with and without contrast to understand better the size and proximity of nearby visceral tissues and neurovascular landmarks. There may be a need for additional computed tomography (CT) scanning with contrast. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the undifferentiated pleomorphic sarcoma therapeutics market are Pfizer Inc., Eisai Inc., AdvaCare Pharma, Teva Pharmaceuticals USA, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, PV Pharma.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

DOXORUBICIN HYDROCHLORIDE: Doxorubicin (DOX) is often first-line treatment of undifferentiated/unclassified soft tissue sarcoma (USTS).

The global undifferentiated pleomorphic sarcoma therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.